Top Markets
Coin of the day
Medtronic plc Medtronic plc

Medtronic plc

2M6
Classement en actions #164
Medtronic plc develops, manufactures, and sells device-based medical therapies... Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Prix de l'action
$88.89
Capitalisation boursière
$114.13B
Changement (1 jour)
-0.93%
Changement (1 an)
-2.08%
Pays
IE
Échange Medtronic plc (2M6)

Catégorie

Ratio P/E pour Medtronic plc (2M6)
Ratio P/E au March 2026 TTM : 24.21
Selon les derniers rapports financiers et le cours de l'action de Medtronic plc, le ratio P/E actuel (TTM) est de 24.21. À la fin de l’année 2024, le P/E de l’entreprise était de 28.98.
Historique du ratio P/E pour Medtronic plc de 2000 à 2026
Ratio P/E à la fin de chaque année
Année Ratio P/E Changez
2026 (TTM) 24.21 3.61%
2025 23.37 -19.35%
2024 28.98 -9.95%
2023 32.18 15.76%
2022 27.80 -43.06%
2021 48.83 75.64%
2020 27.80 9.46%
2019 25.40 -28.52%
2018 35.53 24.91%
2017 28.44 -9.80%
2016 31.53 -0.78%
2015 31.78 65.27%
2014 19.23 40.13%
2013 13.72 23.30%
2012 11.13 -23.39%
2011 14.53 -6.85%
2010 15.60 -5.77%
2009 16.55 -32.91%
2008 24.67 13.60%
2007 21.72 -8.07%
2006 23.62 -33.21%
2005 35.37 13.16%
2004 31.26 -13.97%
2003 36.33 -33.97%
2002 55.03 7.28%
2001 51.29 -9.73%
2000 56.83 0.00%
Ratio P/E pour des entreprises similaires ou concurrentes
Entreprise P/E Ratio Différence du P/E Ratio Pays
28.93 19.47%
US
39.68 63.89%
US
24.21 0.00%
IE
35.47 46.47%
US
20.43 -15.63%
DE
Comment lire un P/E ratio ?

Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.

Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.

Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.